Molecular Subtype of Ovarian Clear Cell Carcinoma: an Analysis of 80 Chinese Patients Using the TCGA Molecular Classification of Endometrial Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Date 2025 Jan 15

PMID 39815187

Authors

Wei Chen

Lu Yan

Qin Li

Shuling Zhou

Ting Hou

Huijuan Yang

Shuang Ye

Affiliations

Soon will be listed here.

Abstract

Background: To assess the utility of the TCGA molecular classification of endometrial cancer in a well-annotated, moderately sized, consecutive cohort of Chinese patients with ovarian clear cell carcinoma (OCCC).

Methods: We performed DNA sequencing on 80 OCCC patients via a panel that contains 520 cancer-related genes. The TCGA molecular subtyping method was utilized for classification. The clinicopathological features were analysed, and the survival correlation was assessed for each subtype.

Results: The most common mutated genes were ARID1A (49%) and PIK3CA (48%). No pathogenic POLE mutations were detected. MSI-high (MSI-H) tumours were observed in 5 (6.3%) patients. A total of 16.3% (13/80) of the patients were classified as the p53 abnormal (p53abn) subtype, and 77.5% (62/80) were classified as the nonspecific molecular profile (NSMP) subtype. All the MSI-H patients had ARID1A mutations, whereas patients with the p53abn subtype had the lowest percentage of ARID1A mutations (27.3%). No significant differences were observed between the molecular subtypes and clinicopathological features. The progression-free survival and overall survival of the entire cohort were closely associated with FIGO stage (p < 0.01), the presence of residual tumour (p < 0.01), and the platinum response (p < 0.01). Molecular classification did not significantly impact prognosis. Univariate analysis revealed that TP53 mutations in advanced-stage (FIGO III-IV) patients were associated with shorter survival.

Conclusions: We did not find prognostic significance of TCGA molecular subtyping in OCCC. POLEmuts are extremely rare, and the incidence of MSI-H and p53abn tumours is also quite low. Further subtyping of the NSMP subgroup is warranted.

References

Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti G . Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021; 162(3):741-750. DOI: 10.1016/j.ygyno.2021.06.033. View

Hajkova N, Kendall Bartu M, Cibula D, Drozenova J, Fabian P, Fadare O . Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes. Transl Res. 2023; 260:61-68. DOI: 10.1016/j.trsl.2023.05.004. View

Zhu L, Huang Y, Fang X, Liu C, Deng W, Zhong C . A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing. J Mol Diagn. 2017; 20(2):225-231. DOI: 10.1016/j.jmoldx.2017.11.007. View

Long D, Waalkes A, Panicker V, Hause R, Salipante S . Identifying Optimal Loci for the Molecular Diagnosis of Microsatellite Instability. Clin Chem. 2020; 66(10):1310-1318. PMC: 7528407. DOI: 10.1093/clinchem/hvaa177. View

Ye S, Zhou S, Wu Y, Pei X, Jiang W, Shi W . Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival. Ann Med. 2023; 55(1):2218104. PMC: 10243386. DOI: 10.1080/07853890.2023.2218104. View

Oliveira D, Schnack T, Poulsen T, Christiansen A, Hogdall C, Hogdall E . Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. Cancers (Basel). 2021; 13(20). PMC: 8533704. DOI: 10.3390/cancers13205242. View

Kobel M, Kang E, Weir A, Rambau P, Lee C, Nelson G . p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2023; 9(3):208-222. PMC: 10073933. DOI: 10.1002/cjp2.311. View

Chen W, Shan B, Zhou S, Yang H, Ye S . Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma. BMC Cancer. 2022; 22(1):92. PMC: 8780809. DOI: 10.1186/s12885-022-09204-0. View

Li C, Tian D, Tang B, Liu X, Teng X, Zhao W . Genome Variation Map: a worldwide collection of genome variations across multiple species. Nucleic Acids Res. 2020; 49(D1):D1186-D1191. PMC: 7778933. DOI: 10.1093/nar/gkaa1005. View

10.

Cybulska P, Da Cruz Paula A, Tseng J, Leitao Jr M, Bashashati A, Huntsman D . Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol. 2019; 154(3):516-523. PMC: 6736779. DOI: 10.1016/j.ygyno.2019.07.012. View

11.

Prat J, DAngelo E, Espinosa I . Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018; 80:11-27. DOI: 10.1016/j.humpath.2018.06.018. View

12.

Bolton K, Chen D, Corona de la Fuente R, Fu Z, Murali R, Kobel M . Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clin Cancer Res. 2022; 28(22):4947-4956. PMC: 9777703. DOI: 10.1158/1078-0432.CCR-21-3817. View

13.

Iida Y, Okamoto A, Hollis R, Gourley C, Herrington C . Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2020; 31(4):605-616. DOI: 10.1136/ijgc-2020-001656. View

14.

Tan T, Ye J, Yee C, Lim D, Ngoi N, Tan D . Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine. 2019; 50:203-210. PMC: 6921362. DOI: 10.1016/j.ebiom.2019.11.017. View

15.

Momeni-Boroujeni A, Nguyen B, Vanderbilt C, Ladanyi M, Abu-Rustum N, Aghajanian C . Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol. 2022; 35(9):1269-1278. PMC: 9427676. DOI: 10.1038/s41379-022-01066-y. View

16.

Chen W, Zhong S, Shan B, Zhou S, Wu X, Yang H . Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. J Ovarian Res. 2020; 13(1):89. PMC: 7415177. DOI: 10.1186/s13048-020-00693-w. View

17.

Ye S, Zhou S, Zhong S, Shan B, Jiang W, Yang W . The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma. BMC Cancer. 2022; 22(1):449. PMC: 9035241. DOI: 10.1186/s12885-022-09588-z. View

18.

McCluggage W, Singh N, Gilks C . Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022; 80(5):762-778. DOI: 10.1111/his.14609. View

19.

. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res. 2021; 50(D1):D27-D38. PMC: 8728233. DOI: 10.1093/nar/gkab951. View

20.

Struzinska I, Hajkova N, Hojny J, Krkavcova E, Michalkova R, Dvorak J . A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations. Diagn Pathol. 2023; 18(1):72. PMC: 10259037. DOI: 10.1186/s13000-023-01358-0. View